ORIENTBIO Announces 50% Capital Reduction to Improve Financial Structure and Shareholder Value
ORIENTBIO announced a 50% capital reduction through a 2:1 share consolidation, decided by the board on June 23, 2026.
The record date is September 4, 2026, and the new shares are expected to be listed on September 22, 2026.
Outstanding shares will decrease from 59,291,502 to 29,645,751, and capital will be halved.
The purpose is to improve financial structure and enhance shareholder value; fractional shares will be paid in cash.
[AI Summary]ORIENTBIO's 50% capital reduction via share consolidation focuses on financial restructuring without capital inflow. Shareholders' number of shares halves but per-share value theoretically doubles, mitigating dilution risk. However, the defensive nature of this move may limit long-term growth catalysts.